Roche eyes October decision by FDA for wet AMD implant

The FDA has started a review of a new implant version of Roche's ranibizumab therapy for wet age-related macular degeneration, that could offer patients with the sight-robbing disorder an a

Novartis halts three trials of Beovu eye drug on safety conc...

Prospects for Novartis' ophthalmology drug Beovu have taken another dive after the drugmaker reported toxicity issues in a new phase 3 trial in wet age-related macular degeneration (AMD).

Bayer slides on €9.5bn loss caused by litigation, COVID-19 i...

Bayer counted the cost of its expensive Roundup weedkiller settlement in the second quarter with a €9.5 billion net loss made worse by lower sales in its pharma and consumer he

Novartis’ blockbuster hope Beovu clears EMA advisory panel

MHRA says Avastin can be used for AMD despite Bayer, Novarti...

Novartis backs brolucizumab with new head-to-head Eylea tria...